PartnershipApr 30, 2026, 08:33 AM
OPK Gets 15% Equity in Nicoya; RAYALDEE China Commercialization
AI Summary
OPKO Health, Inc. announced that its subsidiary EirGen Pharma Limited amended its agreement with Nicoya Therapeutics, granting OPKO a 15% equity stake in Nicoya. This amendment reinforces Nicoya's commitment to commercialize RAYALDEE in Greater China and expands the field of use. The original milestone structure, allowing OPKO to receive up to $115 million, remains unchanged. RAYALDEE is approved in Macau, with regulatory approvals expected in China and related territories in 2027, targeting a significant market of over 20 million adults with chronic kidney disease.
Key Highlights
- OPKO received a 15% equity stake in Nicoya Therapeutics.
- The amended agreement expands the field of use for RAYALDEE in Greater China.
- OPKO is eligible to receive up to $115 million in development, regulatory, and sales-based milestones.
- RAYALDEE is approved in Macau, with expected approvals in China and related territories in 2027.
- China has over 20 million adults affected by stage 3 or 4 chronic kidney disease.
- RAYALDEE was launched in the U.S. in November 2016.